Catalyst

Slingshot members are tracking this event:

Phase 2 additional data of VK2809 in Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease to be presented at EASL April 11, 2019, 09:00 AM CEST

Source Link:
http://ir.vikingtherapeutics.com/2019-03-13-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2018-Financial-Results-and-Provides-Corporate-Update

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VKTX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 11, 2019
Occurred Source:
http://ir.vikingtherapeutics.com/2019-04-11-Viking-Therapeutics-Presents-New-Data-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol-at-The-International-Liver-Congress-TM-2019
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Vk2809, Hypercholesterolemia, Nafld, Easl 2019
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.